In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) has received 6 analyst ratings over the past three months, with a current average 12-month price target of $84.5, up from the previous $80.00. Ratings include 2 bullish and 4 somewhat bullish, with recent actions including raises and maintains by analysts from B of A Securities, Cantor Fitzgerald, TD Cowen, RBC Capital, and Needham. The company has shown a revenue growth rate of 75.05% as of September 30, 2023, but has a net margin of -19.28% and an ROE of -4.02%, indicating potential profitability and efficiency challenges.
January 02, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies has received mostly bullish ratings from analysts, with an increased average price target of $84.5. The company has experienced significant revenue growth but faces profitability and efficiency challenges.
The positive analyst ratings and raised price target suggest a bullish short-term impact on ITCI's stock price. However, the underlying financial challenges such as low net margin and ROE may temper the stock's performance. The high relevance is due to the direct mention of ITCI and detailed analyst ratings. The importance is high as analyst ratings can significantly influence investor sentiment and stock price. The confidence level is set at 80 due to the clear consensus among analysts and reported financial metrics.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100